Insights

Essential reading for decision-makers

by Magnus Ytterstad

The holiday season is upon us, and here is our list of late stocking stuffers for colleagues in drug development, decision analysis and portfolio management.

Leverage the power of linked R&D and sales models!

by Magnus Ytterstad

The last blog post described how to make better forecasts. Now we will explore what it really means to integrate the R&D and commercial forecasting models.

Making confident decisions in pharmaceutical projects

by Magnus Ytterstad

We investigate what it means to have better information when making project investment decisions, starting by getting familiar with the options.

Lessons learned in R&D portfolio forecasting

by Magnus Ytterstad

An earlier blog post touched on how project plans are limited as strategic tools. So, if plans are not useful for strategic decisions, what should we use?

Limitations with eNPV

by Magnus Ytterstad

In pharma industry, expected NPV is widely used as a metric to compare the value of molecules under development. But how representative of value is eNPV?

Treasure maps for drug developers!

by Magnus Ytterstad

How do we make better project decisions in drug development? Let's explore the map and try to find a better way.

Portfolio management – evaluating options (part 4)

by Magnus Ytterstad

We close off our series about new methods for portfolio management and analysis. Concluding with the benefits integrating market- and development models.

Portfolio management – evaluating options (part 3)

by Magnus Ytterstad

Part 3 in our series about new methods for portfolio management and analysis. We continue to investigate what effect uncertainty has on number of launches.

Portfolio management – evaluating options (part 2)

by Magnus Ytterstad

In part 2 of our series about new methods for portfolio management and analysis, we continue our portfolio evaluation by looking into uncertainty and loss.

Portfolio management – evaluating options (part 1)

by Magnus Ytterstad

In part 1 of our series about new methods for portfolio management and analysis we begin by setting up portfolios and looking at portfolio selection.

Using Monte Carlo simulation for launch prediction

by Magnus Ytterstad

Portfolio analysts need to forecast the number of launches from the internal project portfolio. Can Monte Carlo simulation provide additional insight?

Conference report: strategic project and portfolio management

by Magnus Ytterstad

Captario attended the 15th annual Strategic Project and Portfolio management conference in Barcelona. In this post we share some insights from the event.

Best case scenarios – wishful thinking or useful information?

by Mikael Palmblad

As analysts, we often receive requests to create scenarios for a best, or worst case. The purpose is laudable, but does it really improve the decision?

How much is a drug project worth?

by Magnus Ytterstad

The value of drug projects is a hot topic in drug development. Putting a value on a project enables many decisions. But do we understand how to project value?

What is Monte Carlo Simulation?

by Magnus Ytterstad

Monte Carlo simulation is becoming more and more common in drug development decision-making. But what is Monte Carlo simulation?

The best laid plans (or forecasts?)

by Magnus Ytterstad

Understanding the difference between project plans and project forecasts, is critical to increasing value in drug portfolios.

Embracing uncertainty

by Mikael Palmblad

Embracing uncertainty as a quantifiable factor in drug projects is a conceptual change that is critical to increasing portfolio values.

Let us help you make better decisions

Captario offers trials and pilots of Captario SUM®. Our technical staff is ready to help set up a decision-making environment suited to your organization. Get in touch today and start your journey towards better decisions.